JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on February 17, 2006; DOI: 10.1124/jpet.105.099036


0022-3565/06/3173-1114-1124$20.00
JPET 317:1114-1124, 2006
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.105.099036v1
317/3/1114    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Saito, H.
Right arrow Articles by Ishikawa, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Saito, H.
Right arrow Articles by Ishikawa, T.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Medicines
Hazardous Substances DB
*METHOTREXATE

METABOLISM, TRANSPORT, AND PHARMACOGENOMICS

A New Strategy of High-Speed Screening and Quantitative Structure-Activity Relationship Analysis to Evaluate Human ATP-Binding Cassette Transporter ABCG2-Drug Interactions

Hikaru Saito, Hiroyuki Hirano, Hiroshi Nakagawa, Takeaki Fukami, Keisuke Oosumi, Kaori Murakami, Hiroko Kimura, Takayuki Kouchi, Mami Konomi, Eriko Tao, Noboru Tsujikawa, Shigeki Tarui, Makoto Nagakura, Masako Osumi, and Toshihisa Ishikawa

Department of Biomolecular Engineering, Graduate School of Bioscience and Biotechnology, Tokyo Institute of Technology, Yokohama, Japan (H.S., H.N., T.I.); GS PlatZ Co. Ltd., Tokyo, Japan (H.H., S.T.); BioTec Co. Ltd, Tokyo, Japan (T.F., K.O., M.N.); Life Science Division, Nihon Millipore KK, Tokyo, Japan (K.M., H.K., T.K.); Laboratory of Electron Microscopy, Open Research Center, Japan Women's University, Tokyo, Japan (M.K., M.O.); Integrated Imaging Research Support, Tokyo, Japan (E.T., M.O.); and WEISEL Corporation, Tokyo, Japan (N.T.)

The human ATP-binding cassette (ABC) transporter ABCG2 (BCRP/MXR1/ABCP) plays a critical role in cellular protection against xenobiotics as well as pharmacokinetics of drugs in our body. In the present study, we aimed to analyze the quantitative structure-activity relationship (QSAR) latently residing in ABCG2-drug interactions. We first established standard methods for expression of human ABCG2 in insect cells, quality control of plasma membrane samples by using electron microscopy techniques, and high-speed screening of ABCG2 inhibition with test compounds. Plasma membrane vesicles prepared from ABCG2-expressing Sf9 cells were used as a model system to measure the ATP-dependent transport of [3H]methotrexate (MTX). Forty-nine different therapeutic drugs and natural compounds were tested for their ability to inhibit ABCG2-mediated MTX transport. Based on their inhibition profiles, we performed QSAR analysis using chemical fragmentation codes deduced from the structures of test compounds. Multiple linear regression analysis delineated a relationship between the structural components and the extent of ABCG2 inhibition, allowing us to identify one set of structure-specific chemical fragmentation codes that are closely correlated with the inhibition of ABCG2 transport activity. Based on the QSAR analysis data, we predicted the potency of gefitinib to inhibit ABCG2. The validity of our QSAR-based prediction for gefitinib was examined by actual experiments. Our kinetic analysis experiments suggest that the ABCG2-ATP complex binds gefitinib. The present study provides a new strategy for analyzing ABCG2-drug interactions. This strategy is considered to be practical and useful for the molecular designing of new ABCG2 modulators.


Received November 24, 2005; accepted February 16, 2006.

Address correspondence to: Dr. Toshihisa Ishikawa, Department of Biomolecular Engineering, Graduate School of Bioscience and Biotechnology, Tokyo Institute of Technology, Nagatsuta 4259, Yokohama, Kanagawa 226-8501, Japan. E-mail: tishikaw{at}bio.titech.ac.jp




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
P. Matsson, G. Englund, G. Ahlin, C. A. S. Bergstrom, U. Norinder, and P. Artursson
A Global Drug Inhibition Pattern for the Human ATP-Binding Cassette Transporter Breast Cancer Resistance Protein (ABCG2)
J. Pharmacol. Exp. Ther., October 1, 2007; 323(1): 19 - 30.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
A. Tamura, M. Watanabe, H. Saito, H. Nakagawa, T. Kamachi, I. Okura, and T. Ishikawa
Functional Validation of the Genetic Polymorphisms of Human ATP-Binding Cassette (ABC) Transporter ABCG2: Identification of Alleles That Are Defective in Porphyrin Transport
Mol. Pharmacol., July 1, 2006; 70(1): 287 - 296.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics.